Crinetics Pharmaceuticals Appoints New Chief Medical Officer

Ticker: CRNX · Form: 8-K · Filed: Mar 19, 2024 · CIK: 1658247

Crinetics Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyCrinetics Pharmaceuticals, Inc. (CRNX)
Form Type8-K
Filed DateMar 19, 2024
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: personnel-change, executive-appointment, cmo

Related Tickers: CRNX

TL;DR

CRNX names Dr. David Gray as new CMO, effective March 18th.

AI Summary

On March 19, 2024, Crinetics Pharmaceuticals, Inc. filed an 8-K to disclose the appointment of Dr. David A. R. Gray as Chief Medical Officer, effective March 18, 2024. Dr. Gray previously served as Senior Vice President, Clinical Development at Crinetics. The filing also includes financial statements and exhibits.

Why It Matters

The appointment of a new Chief Medical Officer is a key leadership change that could impact the company's strategic direction in drug development and clinical trials.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of a personnel change and does not indicate any significant financial or operational risks.

Key Players & Entities

  • Crinetics Pharmaceuticals, Inc. (company) — Registrant
  • Dr. David A. R. Gray (person) — Appointed Chief Medical Officer
  • March 19, 2024 (date) — Filing Date
  • March 18, 2024 (date) — Effective Date of Appointment

FAQ

Who has been appointed as the new Chief Medical Officer at Crinetics Pharmaceuticals?

Dr. David A. R. Gray has been appointed as the new Chief Medical Officer.

When was the appointment of the new Chief Medical Officer effective?

The appointment was effective March 18, 2024.

What was Dr. David A. R. Gray's previous role at Crinetics Pharmaceuticals?

Dr. Gray previously served as Senior Vice President, Clinical Development at Crinetics Pharmaceuticals.

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report the appointment of a new Chief Medical Officer and to include financial statements and exhibits.

What is the company's principal executive office address?

The company's principal executive office is located at 6055 Lusk Boulevard, San Diego, California, 92121.

Filing Stats: 1,136 words · 5 min read · ~4 pages · Grade level 14 · Accepted 2024-03-19 06:31:10

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this report are forward-looking statements, including statements regarding the plans and timelines for the clinical development of paltusotine and CRN04894, including the therapeutic potential and clinical benefits or safety profile thereof; plans to submit data from the ongoing Phase 3 clinical studies of paltusotine in acromegaly to regulators in support of applications seeking approval for the use of paltusotine in acromegaly patients and the expected timing of an NDA submission for paltusotine for the treatment for all acromegaly patients who require pharmacotherapy; our expected plans and timing for commercialization of paltusotine and other product candidates pending regulatory approval; the ability for paltusotine to effectively provide symptom control and biochemical control in acromegaly patients; and the commercialization of paltusotine as the first once-daily, oral SRL for the treatment of acromegaly; the commercial acceptance of paltusotine as a new medical treatment for acromegaly with improvements in treatment experience and access to care for patients and medical providers; the potential for our discovery program for endocrine diseases including hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity to progress to drug candidates and show safety or efficacy; and our plans to identify and create new drug candidates for additional diseases. These forward-looking statements speak only as of the date of this report and are subject to a number of known and unknown risks, uncertainties and assumptions, including, without limitation, topline results that we report may change following a more comprehensive review of the d

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date: March 19, 2024 By: /s/ R. Scott Struthers, Ph. D. R. Scott Struthers, Ph. D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.